Quinagolide compared with cabergoline in the prevention of ovarian hyperstimulation syndrome: a randomized trial

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Evidence Based Women's Health Journal

• Publication date

  2016-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.EBX.0000440884.67667.d1
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study.

  2012cited by this paper
• Cabergoline for preventing ovarian hyperstimulation syndrome.

  2012cited by this paper
• The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial†

  2010cited by this paper
• Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis.

  2010cited by this paper
• Dopamine agonists and hyperprolactinaemia

  2009cited by this paper
• Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study.

  2008cited by this paper
• Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.

  2007cited by this paper
• Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study.

  2007cited by this paper
• Valvular heart disease and the use of dopamine agonists for Parkinson's disease.

  2007cited by this paper
• Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction.

  2007cited by this paper
• Drugs and valvular heart disease.

  2007cited by this paper
• Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model.

  2006cited by this paper
• Administration of Moderate and High Doses of Gonadotropins to Female Rats Increases Ovarian Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor-2 Expression that Is Associated to Vascular Hyperpermeability1

  2003cited by this paper
• Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade.

  2002cited by this paper
• The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome.

  1997cited by this paper
• Ovarian hyperstimulation syndrome in novel reproductive technologies: Prevention and treatment

  1993cited by this paper
• Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment.

  1992cited by this paper
• Ovarian hyperstimulation syndrome: A review of pathophysiology

  1992cited by this paper
• Modern management of ovarian hyperstimulation syndrome.

  1991cited by this paper

• EFFECT OF THE CABERGOLINE IN IMPLANTATION WHEN ADMINISTERED TO PREVENT OVARIAN HYPERSTIMULATION SYNDROME

  2022cites this paper
• Comparison of Cabergoline and Quinagolide in Prevention of Severe Ovarian Hyperstimulation Syndrome among Patients Undergoing Intracytoplasmic Sperm Injection

  2018cites this paper
• Cabergoline versus Quinagolide for the Management of Macroprolactinoma and Erectile Dysfunction: A Randomized, Open-Label Study

  2018cites this paper